Hormonal
Obesity causes structural and functional cardiac alterations, including left ventricular hypertrophy, diastolic dysfunction, and atrial fibrillation, primarily through increased blood volume, cardiac output, and neuro-hormonal activation (RAAS).
Excess body weight forces your heart to work harder by increasing blood volume and output, leading to thickening of the heart muscle (LVH) and stiffening of the heart chambers. This structural change happens even if you feel no symptoms and increases the risk of heart failure and arrhythmias like atrial fibrillation.
Obesity increases blood volume, stroke volume, and cardiac output, which results in an increase in cardiac work. These alterations also lead to LV dilatation and left ventricular hypertrophy (LVH)... obesity leads to enlargement of the left atrium... which increases the risk of HF.
Why this rating
Supported by multiple citations and established pathophysiological descriptions in the review.
Source
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Jorge Gutiérrez‐Cuevas et al. · International Journal of Molecular Sciences · 2021
DOI 10.3390/ijms222111629
More from this paper
- Obesity-induced adipose tissue dysfunction and systemic insulin resistance drive the development of MAFLD/NASH, which in turn exacerbates cardiovascular disease risk through the release of pro-atherogenic, pro-coagulant, and pro-inflammatory mediators from the liver.Good
- Insulin resistance is a major cardiovascular risk factor in subjects without diabetes and serves as a key link between MAFLD/NASH and cardiovascular disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →